Segment Information (Tables)

12 Months Ended

Dec. 31, 2012

Segment Reporting [Abstract]

Reconciliation Of Segment Information To Total Consolidated Information

Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.

(In thousands)	Generics Segment		Specialty Segment		Corporate / Other(1)			Consolidated
Year Ended December 31, 2012
Total revenues
Third party	$	5,946,203	$	849,907	$	—		$	6,796,110
Intersegment	3,088		36,991		(40,079		)	—
Total	$	5,949,291	$	886,898	$	(40,079	)	$	6,796,110
Segment profitability	$	1,706,783	$	319,243	$	(916,677	)	$	1,109,349

(In thousands)	Generics Segment		Specialty Segment		Corporate / Other(1)			Consolidated
Year Ended December 31, 2011
Total revenues
Third party	$	5,544,975	$	584,850	$	—		$	6,129,825
Intersegment	2,480		70,005		(72,485		)	—
Total	$	5,547,455	$	654,855	$	(72,485	)	$	6,129,825
Segment profitability	$	1,607,910	$	240,440	$	(842,901	)	$	1,005,449

(In thousands)	Generics Segment		Specialty Segment		Corporate / Other(1)			Consolidated
Year Ended December 31, 2010
Total revenues
Third party	$	5,012,422	$	438,100	$	—		$	5,450,522
Intersegment	40,116		61,772		(101,888		)	—
Total	$	5,052,538	$	499,872	$	(101,888	)	$	5,450,522
Segment profitability	$	1,388,736	$	132,222	$	(799,374	)	$	721,584

____________

⁽¹⁾  Includes certain corporate general and administrative and research and development expenses; net charges for litigation settlements; certain intercompany transactions, including eliminations; amortization of intangible assets and certain purchase accounting items; impairment charges; and other expenses not directly attributable to segments.

Net Revenues Classified Based On Therapeutic Product Categories

The Company’s net revenues are generated via the sale of products in the following therapeutic categories:

	Year Ended December 31,
(In thousands)	2012		2011		2010
Allergy	$	741,487	$	476,990	$	343,138
Anti-infectives	1,034,332		1,005,278		783,738
Cardiovascular	1,156,348		1,037,644		967,680
Central Nervous System	1,473,928		1,214,046		1,248,982
Dermatological	157,296		143,769		166,200
Endocrine and Metabolic	645,936		535,383		433,341
Gastrointestinal	418,934		492,683		462,088
Respiratory System	229,249		250,692		248,452
Other (1)	892,736		949,792		750,647
	$	6,750,246	$	6,106,277	$	5,404,266

____________

⁽¹⁾  Other consists of numerous therapeutic classes, none of which individually exceeds 5% of consolidated net revenues.

Net Revenues Classified Based On Geographic Location Of Customers

The Company’s principal geographic markets are North America, EMEA, and Asia Pacific. Net revenues are classified based on the geographic location of the customers and are as follows:

	Year Ended December 31,
(In thousands)	2012		2011		2010
The Americas:
United States	$	3,909,518	$	3,242,985	$	2,656,532
Other Americas	221,898		226,144		188,659
Europe (1)	1,694,236		1,781,184		1,790,901
Asia	924,594		855,964		768,174
	$	6,750,246	$	6,106,277	$	5,404,266

 ____________

⁽¹⁾  Net revenues in France consisted of approximately 9%, 11% and 13% of consolidated net revenues for the years ended December 31, 2012, 2011 and 2010, respectively.